ELA vs TSLA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Envela Corporation (ELA) presents a stark dichotomy between explosive growth and deteriorating fundamental health. While the company exhibits hyper-growth in revenue (66.6%) and earnings (284.5%), the Piotroski F-Score of 3/9 indicates weak financial health and poor operational efficiency. The stock is currently trading at a premium ($18.50) relative to both its Graham Number ($5.70) and Intrinsic Value ($16.52), with a concerning Forward P/E (52.86) that exceeds its trailing P/E (33.04), suggesting a projected earnings slowdown.
Tesla's deterministic health is marginally stable with a Piotroski F-Score of 4/9, but the valuation is fundamentally decoupled from financial performance. The stock trades at a massive premium to its Graham Number ($23.07) and Intrinsic Value ($7.56), while exhibiting negative revenue growth (-3.10%) and a severe collapse in earnings growth (-60.60%). With zero earnings beats in the last four quarters and bearish insider activity, the current price is supported by sentiment rather than data.
Compare Another Pair
Related Comparisons
ELA vs TSLA: Head-to-Head Comparison
This page compares Envela Corporation (ELA) and Tesla, Inc. (TSLA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.